Eton Pharmaceuticals, Inc. Interest Income (Expense), Nonoperating, Net
Eton Pharmaceuticals, Inc. (ETON) reported Interest Income (Expense), Nonoperating, Net of -$1.08 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Income Statement › Other Income
us-gaap:InterestIncomeExpenseNonoperatingNet · last filed 2026-08-13
- Eton Pharmaceuticals, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-06-30 was -$1.08M.
- Eton Pharmaceuticals, Inc. interest income (expense), nonoperating, net for the quarter ending 2026-03-31 was -$840.00K.
- Eton Pharmaceuticals, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-09-30 was -$592.00K.
- Eton Pharmaceuticals, Inc. interest income (expense), nonoperating, net for the quarter ending 2025-06-30 was -$1.04M.
| Period end | Interest Income (Expense), Nonoperating, Net 3 month | Interest Income (Expense), Nonoperating, Net 6 month | Interest Income (Expense), Nonoperating, Net 9 month |
|---|---|---|---|
| 2026-06-30 | -$1.08M 10-Q · filed 2026-08-13 | -$1.92M 10-Q · filed 2026-08-13 | |
| 2026-03-31 | -$840.00K 10-Q · filed 2026-05-14 | ||
| 2025-09-30 | -$592.00K 10-Q · filed 2025-11-06 | -$1.64M derived: sum of 2 quarters · filed 2026-08-13 | -$2.66M 10-Q · filed 2025-11-06 |
| 2025-06-30 | -$1.04M 10-Q · filed 2026-08-13 | -$2.07M 10-Q · filed 2026-08-13 | |
| 2025-03-31 | -$1.03M 10-Q · filed 2026-05-14 | ||
| 2024-09-30 | -$8.00K 10-Q · filed 2025-11-06 | -$60.00K derived: sum of 2 quarters · filed 2025-11-06 | -$71.00K 10-Q · filed 2025-11-06 |
| 2024-06-30 | -$52.00K 10-Q · filed 2025-08-07 | -$63.00K 10-Q · filed 2025-08-07 | |
| 2024-03-31 | -$11.00K 10-Q · filed 2025-05-13 | ||
| 2023-09-30 | -$31.00K 10-Q · filed 2024-11-12 | -$155.00K derived: sum of 2 quarters · filed 2024-11-12 | -$281.00K 10-Q · filed 2024-11-12 |
| 2023-06-30 | -$124.00K 10-Q · filed 2024-08-08 | -$250.00K 10-Q · filed 2024-08-08 | |
| 2023-03-31 | -$126.00K 10-Q · filed 2024-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |